Momenta Pharmaceuticals (NASDAQ: MNTA) continued the slow grind of drug development in the second quarter while it tries to decide the best course of action to maximize the value of its pipeline.MetricQ2 2018Continue reading
newsfeedback@fool.com (Brian Orelli), The Motley Fool
Mon, 08/13/2018 - 12:30pm
Momenta Pharmaceuticals (NASDAQ: MNTA) continued the slow grind of drug development in the second quarter while it tries to decide the best course of action to maximize the value of its pipeline.MetricQ2 2018Continue reading